Physician profile
Alan N Kohn
NPI 1649242363
$1,732.95
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $772 · 2020: $99.19 · 2021: $861.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $253.48 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $220.35 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $161.00 | 2019-2021 | |
| Dompe US, INC. | $158.63 | 2021 | |
| Kala Pharmaceuticals, INC. | $145.77 | 2019-2021 | |
| Biotissue Holdings INC. | $134.75 | 2021 | |
| Allergan, INC. | $129.36 | 2019 | |
| Sight Sciences, INC. | $122.07 | 2019 | |
| Omeros Corporation | $109.27 | 2021 | |
| Spark Therapeutics, INC. | $105.68 | 2019 | |
| Ivantis, INC | $99.19 | 2020 | |
| Mallinckrodt Hospital Products INC. | $52.08 | 2021 | |
| Eyevance Pharmaceuticals LLC | $21.14 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $20.18 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Kohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.